

FORBIUS

Ability of AVID200, a Novel TGF-beta Inhibitor, to Enhance Immune Cell Infiltration and Efficacy of Immune Checkpoint Inhibition Featured at the Keystone Symposia On Cancer Immunotherapy

- Presentation will take place March 11 at 7:30 PM PST (Poster Session 1, Sea to Sky A)
- Immunosuppression and fibrosis in tumor stroma reversed by AVID200 in syngeneic mouse models, leading to enhanced anti-PD-L1 blockade efficacy
- AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the main oncogenic TGF-beta isoforms
- AVID200 Phase 1 dose escalation solid tumor trial ongoing

Austin, TX, and Montreal, QC (Mar. 11, 2019) – Forbius, a clinical-stage company that develops novel biologics for the treatment of fibrosis and cancer, announces a presentation of AVID200 preclinical data at the [Keystone Symposia on Cancer Immunotherapy](#), March 10 – 14.

This presentation describes AVID200's immuno-oncology mode of action and ability to increase T-cell-mediated cytotoxicity and immune cell infiltration, resulting in enhanced efficacy of immune checkpoint inhibitors in syngeneic mouse tumor models.

TGF-beta 1 & 3 are the main oncogenic TGF-beta isoforms expressed by many solid tumors. They are believed to play a major role in T-cell suppression, fibrosis, and resistance to anti-PD-(L)1 therapies such as nivolumab (Opdivo®) and pembrolizumab (Keytruda®) ([Chakravarthy et al., Nature Comm., 2018](#); [Tauriello et al., Nature, 2018](#); [Mariathasan et al., Nature, 2018](#)).

Presentation Details:

AVID200, a potent TGF-β trap designed for optimal selectivity and tolerance, sensitizes tumors to immune checkpoint blockade therapy.

Poster presentation: March 11, 7:30 – 10:00 PM PST (Poster Session 1, Sea to Sky A)

About AVID200: TGF-beta 1 & 3 Inhibitor

AVID200 is a rationally designed, highly potent TGF-beta 1 & 3 inhibitor undergoing Phase 1 clinical testing in solid tumors and fibrotic diseases. TGF-beta 1 & 3 are the principal disease-driving isoforms, while TGF-beta 2 is responsible for normal cardiac function and hematopoiesis.

AVID200's selectivity for TGF-beta 1 & 3 was designed to achieve optimal efficacy, while circumventing cardiac and other safety issues that have limited the applicability of older-generation, non-selective TGF-beta inhibitors. Therefore, AVID200 is positioned to be an effective and well-tolerated therapeutic in a variety of clinical settings, including in combination with anti-PD-(L)1 therapy.

About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

Forbius is a clinical-stage protein engineering company that designs and develops novel biologics for the treatment of fibrosis and cancer. Our current focus is the development of agents that target the transforming growth factor-beta (TGF-beta) as well as the epidermal growth factor receptor (EGFR) pathways. For more information, please visit www.forbius.com.